TMCnet News
Stock Hunter Presents!! ECOF,MVIS,IWEB,IMGG,CCTC,KERX:: Sign Up Today!!(M2 PressWIRE Via Acquire Media NewsEdge) Stock Hunter PRESENTS : PINKSHEETS: ECOF) Eco2 Forests Inc., (NASDAQ) MVIS -Microvision, Inc., (OTCBB: IWEB) IceWEB, Inc., (OTCBB: IMGG) Imaging3, Inc., (PINKSHEETS: CCTC) Clean Coal Technologies, Inc., (NASDAQ: KERX) Keryx Biopharmaceuticals, Inc. www.Stockhunter.us To sign up for our free Profiles & Alerts :: visit http://www.StockHunter.us Email us!! [email protected] ------------------------------------------------------------------------------------------------------------------------------------------------------------ (PINKSHEETS: ECOF - Eco2 Forests Inc.) LATEST NEWS!! ECO2 Forests Announce Sustainable Forest Project on US Soil SACRAMENTO, CA and QUEENSLAND, AUSTRALIA, Apr 06, 2010 -- ECO2 Forests Inc. (PINKSHEETS: ECOF) has announced its first Global Forestry Plan project on US soil will be a planned 14,000 acre Kiri Tree forest program in Washoe County, Nevada. The project will be known as the US Sustainable Forest Program located in Washoe County, Nevada and is intended to result in up to 3 million Kiri Trees planted on US soil. This is the first such project in the United States of this magnitude. "ECO2 Forests intends to establish a Program of Sustainable Forest projects in Washoe County, Nevada. Each project is forecast to contain approximately 2,000 acres of land to be forested. The Smoke Creek Project is the first project, planned to commence immediately. It is the first phase of a 14,000 acre program of 7 such forecasted projects forming the US Sustainable Forest Program," ECO2 Forests CEO Collie Christensen said today. "Due to the unique regenerative nature of the Kiri Tree being planted and its ability to regrow from the stump after each harvest, the project is planned to operate for approximately 50 years, subject to certain conditions. This period coincides with the lease terms of the total 78,000 acre network of ranches which includes the water rights to ensure sufficient irrigation for the entire project." After seven years the Kiri Tree reaches maturity and operates in a sustainable cycle. This is forecast to produce in excess of $220 million of revenue per year for the Washoe County US Sustainable Forest Program. As average operational costs are expected to be contained around 20%, this projection would result in significant potential profits to the Company and is anticipated to deliver long term returns to our shareholders. Sustainable lumber production is forecast to deliver 80 million board feet (190,000m3) annually. The sustainable forest naturally regenerates after each seven year harvest, negating the need to replant or log other parcels of forested land that have existed in many cases for centuries. "This is a fantastic project for ECO2 Forests, our land partners, associates and for our forests that are under threat from logging in the United States. By growing our sustainable forests we can help stop the logging of forests that have existed for hundreds of years and enjoyed by thousands of families every year," remarked Christensen. In accordance with the ECO2 Forests E4 Philosophy, the local economy would receive a significant boost with local employment. "ECO2 Forests anticipate that we will employ 280 US workers who live in the local area which we hope will provide another boost to the local economy, with the planned commencement of planting in mid-May of the initial nursery site," Christensen added. Additional capital raising of up to an initial $10 million to accredited investors has already commenced. This capital raising is aimed to ensure the project is suitably funded to maximize returns for investors and to deliver shareholder value for ECO2 Forests shareholders. Direct investment opportunities into the US Sustainable Forest Program are now available to suitable accredited Investors. Eligibility is subject to US state and federal regulation. All details are located through the 'Investors' portal on the ECO2 Forests website, www.eco2forest.com. The information below represents the company forecasts on the entire project based on the sustainable cycle model in the Global Forestry Plan. The projected figures from the project in full operation*: Full 7-Year cycle -- 14,000 acres -- 3 million Kiri Trees planted -- 560 million board feet (1.3 million m3) of sustainable lumber produced for sale -- $1.49 billion in sales of sustainable lumber -- 6.5 million tonnes of CO2 absorbed from the atmosphere (carbon sequestration) -- 6.5 million carbon credits generated -- $84 million carbon credit sales Total projected revenue per full 7-year cycle -- $1.5 billion Annual revenue -- 2,000 acres in full operation*: -- 450,000 Kiri Trees planted -- 80 million board feet (1.3 million m3) of sustainable lumber harvested for sale, every seven years -- $213 million in sales of sustainable lumber -- 923 million tons of CO2 absorbed from the atmosphere (carbon sequestration) -- 6.5 million carbon credits generated -- $12 million carbon credit sales Total projected annual revenue -- $225 million *All figures are based on company forecasts and industry analysis of lumber and carbon credit at industry wholesale prices. About ECO2 Forests Inc. ECO2 Forests is a progressive international forestry company focused on reforestation, afforestation and avoided deforestation projects for the generation and sale of sustainable lumber and carbon credits to the global markets. Headquartered in Sacramento, California, the Company has adopted an 'E4 Philosophy' to achieve positive Environmental, Economic, Employment and Educational outcomes through its projects. For more information please visit www.eco2forests.com. ------------------------------------------------------------------------------------------------------------------------------------------------------------ (NASDAQ - MVIS -Microvision, Inc.) LATEST NEWS!! Microvision Receives $8.5 Million Purchase Order for New PicoP Laser Projection Display Engine REDMOND, Wash., Apr 05, 2010 -- Microvision (NASDAQ: VIS), a leading developer of ultra-miniature projection display products, announced today that it has received an $8.5 million purchase order for its new ultra-miniature PicoP(R) laser projection display engine from a consumer electronics customer. The OEM plans to embed the PicoP engine inside a high-end mobile media player for release in late 2010 and plans to announce its launch at that time. Microvision recently announced the completion and shipment of initial samples of its new display engine that incorporates a proprietary ASIC chipset half the original size and weight and that consumes one third less power than its predecessor while delivering uniformly bright, vivid color WVGA (848 X 480) images up to 200 inches. It also provides a 5000:1 contrast ratio -- 5 times greater than other pico projector engines in the market today and is always in focus without the need for focusing dials or optics - an especially desirable benefit for mobile consumers. "We are very pleased to receive the first purchase order for our new display engine," said Alexander Tokman, President and CEO of Microvision. "This embedded application in a high-end mobile media player is part of our strategy to develop multiple premium distribution channels as we continue to advance the PicoP engine design and mature production capacity to meet anticipated demand across a variety of consumer electronic products including handsets." About Microvision Microvision provides the PicoP display technology platform designed to enable next-generation display and imaging products for pico projectors, vehicles displays, and wearable displays that interface to mobile devices. The company's projection display engine uses highly efficient laser light sources which can create vivid images with high contrast and brightness. For more information, visit the company's website (www.microvision.com) ------------------------------------------------------------------------------------------------------------------------------------------------------------ (OTCBB: IWEB - IceWEB, Inc.) LATEST NEWS!! IceWEB's Channel Partner James River Technical Lands Order From Navy Company Utilizes SEWP Contract to Penetrate Department of Defense STERLING, Va., April 5, 2010 -- IceWEB, Inc.(TM) (OTC Bulletin Board: IWEB), a leading provider of Unified Data Storage, building blocks for cloud storage networks, and purpose-built appliances, announced today that the Company's IceWEB Storage System has been selected as the foundation to build an iSCSI (Internet Small Computer System Interface) Storage platform for a cloud computing virtual server project by its premier federal partner, James River Technical, Incorporated (JRTI), www.jrti.com. This is a one year task order with four option years. Virtual Server or Cloud software provides a completely virtualized set of hardware to the guest operating system. Cloud software virtualizes the hardware for a video adapter, a network adapter, and hard disk adapters. In this way, Cloud computing virtual machines become highly portable between computers, because every host looks nearly identical to the guest. In practice, a system can automatically pause operations on a virtual machine guest, move or copy that guest to another physical computer, and there resume execution exactly at the point of suspension. Alternately, for enterprise servers, a feature called Motion allows the migration of operational guest virtual machines between similar but separate hardware hosts sharing the same storage. Each of these transitions is completely transparent to any users on the virtual machine at the time it is being migrated. The IceWEB storage system was developed to interact seamlessly in these data intensive environments. It is perfectly suited for customers looking to rapidly deploy a simple, advanced and affordable platform. "The initial order is a multi-terabyte solution that is expected to grow exponentially once the baseline system is functional and proven to meet the security threshold standard as set forth in the SEWP (Solutions for Enterprise-wide Procurement) task order," said Jeff Fettig, VP of Sales for JRTI. "The performance and advanced features of this product make it a natural lead in for us. We look forward to doing proactive marketing and lead generation programs with IceWEB and their experienced team of storage professionals." Timothy J. McNamee, Channel Sales Manager, IceWEB Mid-Atlantic region stated, "Having our products available on the SEWP contract combined with JRTI's customer relationships is a match made in heaven. The business development team at JRTI understands how to put together a cost competitive bid that meets or exceeds the technical specifications required by the Federal Government contracting officers making the decisions. We are going to continue to leverage the experienced bid and proposal teams at JRTI." About James River Technical Inc. James River Technical (JRT) is a leading provider and integrator of innovative and cost-effective High Performance Computing solutions. JRT, founded in 1988, is located in Richmond, Virginia. We maintain a nationwide coverage model throughout the US, allowing us to provide a consistent and efficient delivery model for our products and services throughout the country. Contact [email protected]. About IceWEB, Inc. Headquartered just outside of Washington, D.C., IceWEB manufactures and markets data storage products, network and cloud storage solutions and delivers on-line cloud computing application services. Its customer base includes U.S. government agencies, enterprise companies, and small to medium sized businesses (SMB). For more information, please visit www.IceWEB.com. ------------------------------------------------------------------------------------------------------------------------------------------------------------ (OTCBB: IMGG - Imaging3, Inc.) LATEST NEWS!! Imaging3 Announces FDA Submission BURBANK, CA, Apr 05, 2010 -- Imaging3(TM), Inc. (OTCBB: IMGG), developer of a breakthrough medical imaging device that produces 3D medical diagnostic images of virtually any part of the human body in real-time, announced that today, Monday April 5, 2010, Dean Janes, CEO of Imaging3, Inc., submitted the company's latest response to the FDA. If you have any questions, please feel free to contact us by e-mail or directly by calling (800) 900-9729. About Imaging3 Imaging3, Inc., founded in 1993, is a leading provider of advanced technology medical imaging devices. The Company has developed a breakthrough medical imaging device that produces 3D medical diagnostic images of virtually any part of the human body in real-time. Because these 3D images are instantly constructed in real-time, they can be used for any current or new medical procedures in which multiple frames of reference are required to perform medical procedures on or in the human body. Visit the company's website at http://www.imaging3.com for more information ------------------------------------------------------------------------------------------------------------------------------------------------------------ (PINKSHEETS: CCTC - Clean Coal Technologies, Inc.) LATEST NEWS!! Clean Coal Technologies Inc. to Be Featured in Business Week Magazine CORAL SPRINGS, Fla., Apr 05, 2010 -- CLEAN COAL TECHNOLOGIES INC (Pink Sheets: CCTC) announced today that their multi-million-dollar deals in both China and India have been featured in Bloomberg's Business Week magazine, in addition to an overview of its business model, and foreign and domestic plans. President of Clean Coal Technologies Inc. Doug Hague stated: "It is a tremendous honor and significant milestone for CCTI to have Bloomberg's Business Week magazine showcase our Company. This further illustrates the increasing awareness and potential of our clean coal solutions to address critical environmental issues." "We believe that our patented technology, coupled with our unique business model, places CCTI in the forefront of this market, and consequently is in an ideal position to capitalize on its enormous potential." "In trademarking the name 'PRISTINE' to differentiate the characteristics of our product from traditional coal, we will provide the transitional bridge between existing energy solutions and those of the future." "This is an exciting time for our company with so many opportunities for growth," Hague concluded. "We look forward to expanding our business model globally and have developed the team and strategic relationships to ensure we get the job done." ------------------------------------------------------------------------------------------------------------------------------------------------------------ (NASDAQ : KERX - Keryx Biopharmaceuticals, Inc.) LATEST NEWS!! Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Refractory Advanced Colorectal Cancer NEW YORK, April 5, 2010 -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for KRX-0401 (perifosine), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, for the treatment of refractory advanced colorectal cancer. The Fast Track program of the FDA is designed to facilitate the development and expedite the review of new drugs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs. Fast Track designated drugs ordinarily qualify for priority review, thereby expediting the FDA review process. A randomized, double-blind Phase 3 trial investigating perifosine in combination with capecitabine (Xeloda(R)) versus placebo in combination with capecitabine in patients with refractory advanced colorectal cancer is expected to commence in the second quarter of 2010 under a Special Protocol Assessment (SPA) with the FDA. Ron Bentsur, Chief Executive Officer of Keryx Biopharmaceuticals, commented, "We believe that this Fast Track designation adds substantial value to perifosine's development in refractory advanced colorectal cancer. We intend to initiate the Phase 3 colorectal study in the second quarter, with study completion expected in the second half of 2011. With the SPA and Fast Track designation in place, we believe that commercialization of perifosine in this indication could potentially commence by mid-2012." In addition to colorectal cancer, perifosine is currently in a Phase 3 trial, under SPA, for the treatment of relapsed/refractory multiple myeloma, with Orphan Drug Status and Fast Track designation granted. KRX-0401 (perifosine) is in-licensed by Keryx from Aeterna Zentaris, Inc. (Nasdaq: AEZS; TSX: AEZ) in the United States, Canada and Mexico. About KRX-0401 (perifosine) KRX-0401 (perifosine) is a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. The effects of KRX-0401 on Akt are of particular interest because of the importance of this pathway in the development of most cancers, with evidence that it is often activated in tumors that are resistant to other forms of anticancer therapy, and the difficulty encountered thus far in the discovery of drugs that will inhibit this pathway without causing excessive toxicity. High levels of activated Akt (pAkt) are seen frequently in many types of cancer and have been correlated with poor prognosis. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. About Colorectal Cancer According to the American Cancer Society, colorectal cancer is the third most common form of cancer diagnosed in the United States. It is estimated that over 146,000 people were diagnosed with some form of colorectal cancer with over 49,000 patients dying from colorectal cancer in 2009. Surgery is often the main treatment for early stage colorectal cancer. When colorectal cancer metastasizes (spreads to other parts of the body such as the liver) chemotherapy is commonly used. Treatment of patients with recurrent or advanced colorectal cancer depends on the location of the disease. Chemotherapy regimens (i.e. FOLFOX or FOLFIRI either with or without bevacizumab) have been shown to increase survival rates in patients with metastatic/advanced colorectal cancer. Currently, there are seven approved drugs for patients with metastatic/advanced colorectal cancer: 5-fluorouracil (5-FU), capecitabine (Xeloda(R)), irinotecan (Camptosar(R)), oxaliplatin (Eloxatin(R)), bevacizumab (Avastin(R)), cetuximab (Erbitux(R)), and panitumumab (Vectibix(R)). Depending on the stage of the cancer, two or more of these types of treatment may be combined at the same time or used after one another. For example, FOLFOX combines 5-FU, leucovorin and oxaliplatin and FOLFIRI combines 5-FU, leucovorin and irinotecan. Bevacizumab, a VEGF monoclonal antibody, is commonly administered with chemotherapy. Typically, patients who fail 5-FU, oxaliplatin, irinotecan, and bevacizumab-containing therapies, and who have wild-type KRAS status receive EGFR monoclonal antibody therapy with either cetuximab or panitumumab. Once patients progress on these agents, there are no further standard treatment options. About Keryx Biopharmaceuticals, Inc. Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 is currently in a Phase 3 trial, under Special Protocol Assessment (SPA), in multiple myeloma, with a Phase 3 trial in refractory advanced colorectal cancer, under SPA, pending commencement, and in Phase 2 clinical development for several other tumor types. Keryx is also developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex in the treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is pending commencement under an SPA agreement with the FDA. Keryx is headquartered in New York City. ------------------------------------------------------------------------------------------------------------------------------------------------------------ About StockHunter.us StockHunter.us is a website that profiles stocks of interest. We are not licensed brokers or financial consultants. The information here is believed to be reliable, but not guaranteed to be accurate by StockHunter.us. Please be advised that the information contained may or may not be complete and is solely for informational purposes only. This is not to be construed as an offer to sell, hold or the solicitation of an offer to buy. Investors are encouraged to seek opinions by their registered brokers or financial advisors after extensive due diligence is performed. ((Comments on this story may be sent to [email protected])) (c) 2010 M2 COMMUNICATIONS |